Dose Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Dose data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Dose Data Today - Breaking & Trending Today
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
To apply for authorization. there was an add layer as you mentioned, which is that they were encouraged to apply for authorization which gives a sense that the regulators have seen something encouraging in the date. a the only thing we heard until today, late last night, was that the two doses in children between amings of 2 and 5 did not seem to be generating a strong immune response. so i don t know if the regulators are saying we re very encouraged that a third dose will be enough to generate that immune response but we don t want to wait for the third dose data. we think it is time get moving and hopefully get two doses out there. we don t know. hopefully when the fda looks at this data, they release it, we ll get a better sense of what s going on. are there any risks at all, kids this small, 6 months to 5 years old, getting the vaccine? according to the company, that s the only data, the only sense we have of things. we haven t seen the data. they say there has not been ....
Two-dose vaccine ages for the higher range, 2 to 5 or 2 to 4, didn t show much antibody production or didn t show much increase in boosted immunity. totally safe. they found it was totally safe which is why they re willing to give an authorization right now, but what s interesting to me is why move forward until they ve seen data that it s protective? yeah. that is the big question. i think for up until just recently i think the thinking was let s wait to see what that third dose data sort of shows here. i think the belief is that, look, we have this other data from older children. we have seen what the boost the third dose might actually do. should we wait to get that third dose data which would be end of march or later than that or should we say based on the fact that we see that the safety data looks good, it s two doses while in six months and 24 months did ....
Much of an immune response, it is safe so we should get started on getting shots into kids arms. one quote from the washington post on this. we know two doses isn t enough and we get that, says one of the people familiar with the situation. the idea is, let s go ahead and start the review of two doses. if the data holds up in the submission, you could start kids on their primary baseline months earlier than if you don t do anything until the third dose data comes in. what do you think of that? that assume that the third dose works, it s safe and effective, which is an assumption i think no one will make. anything we recommend going forward stands alone as something that is safe and something that s effective for children. we re not going to count on future data to make sure that things work. i don t think it s going to play out that way, but again, we don t all know the data. we re trying to read between the lines with what people mean with what nthey say. february 15th, we ll see ....